前列腺癌PET/CT的变异与陷阱:PET上可能见到且不应忘记的表现
本文为综述,系统总结前列腺癌PET/CT中三种常用示踪剂([11C]或[18F]F-Choline、[18F]F-Fluciclovine、[68Ga]Ga-PSMA及FDA批准的[18F]F-DCFPyl)的生理分布、变异与陷阱,强调正确判读依赖对示踪剂生理分布及可能变异/陷阱摄取的认识,并提及EAU指南中PET在前列腺癌不同分期的多种适应症。
要点
- 前列腺癌PET常用示踪剂包括胆碱、氟昔洛韦和PSMA靶向药物,各有独特生理分布。
- 正确判读需掌握示踪剂生理分布及可能变异/陷阱摄取,避免误判。
- 文献报道了示踪剂变异、陷阱及偶然发现的非前列腺疾病(良恶性)。
核心结论
- 正确判读前列腺癌PET/CT依赖对示踪剂生理分布及可能变异和陷阱摄取的综合认识。
研究设计与样本
- 本文为临界综述,旨在全面提供三种常用示踪剂(胆碱、氟昔洛韦、PSMA靶向药物)的生理分布知识及变异与陷阱的最新概览。
主要发现
- 日常实践中三种最常用PET分子为[11C]或[18F]F-Choline、[18F]F-Fluciclovine和[68Ga]Ga-PSMA,近期FDA批准了首个氟化PSMA药物[18F]F-DCFPyl。
- 越来越多的病例报告和研究报道了示踪剂变异、陷阱或偶然检出的非前列腺疾病(良性和恶性)。
- FDG PET在前列腺癌成像中限于选择病例,主要为晚期前列腺癌和PSMA放射性配体治疗筛选。
临床怎么用
- 判读前列腺癌PET/CT时需结合示踪剂生理分布知识,注意识别变异、陷阱及偶然发现的非前列腺病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
2-deoxy-2-[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) gained an impressive role in the diagnostic management of many oncological diseases, even though its use in imaging prostate cancer (PC) is limited to selected cases, mostly advanced stage of PC and selection for prostate specific antigen membrane (PSMA) radioligand therapy (RLT). In the past years, several PET tracers have been developed for both staging and restaging PC. The three most employed PET molecules in daily practice are [11C] or [18F]F-Choline, [18F]F-Fluciclovine (Anti-1- amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid, also known as (Anti-[18F]FACBC), [68Ga]Ga-PSMA and recently FDA approved the first Fluorinated PSMA-based named [18F]F-DCFPyl. Each one has its own physiological and peculiarity which are worth exploring. Moreover, an increasing number of case reports and studies have reported tracers' variants, pitfalls, or even non-prostatic diseases (benign and malignant) incidentally detected. In prostate oncology, PET can be performed with several indications in different stages of disease, as highlighted in the EAU Guidelines on PC. A correct scan interpretation depends on the knowledge of both the physiological distribution of the tracers and the uptake of possible variants and pitfalls. The aim of this critical review is to provide a comprehensive knowledge of physiological distribution of these three tracers, as well as an updated overview of variants and pitfalls.
引用
- Mei R, Farolfi A, Castellucci P, et al. PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget. Semin Nucl Med. 2021. PMID: 34266631. doi:10.1053/j.semnuclmed.2021.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。